Relative Oral Bioavailability of Levoketoconazole and Ketoconazole in Healthy Subjects

Phase 1, randomised, open-label trial of levoketoconazole in Cushing's syndrome (2 arms), sponsored by Strongbridge Biopharma. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration at 24 hours, Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity at 24 hours and 1 more. Started Dec 2019; status: completed.